Evidence map›Paper›PMID 35241036›Full record

ArticleBMC pediatrics2022

Half-life time prediction of developing first-line antiretroviral treatment failure and its risk factors among TB and HIV co-infected children in Northwest Ethiopia; multi setting historical follow-up study.

Ermias Sisay Chanie, Achenef Asmamaw Muche, Mengistu Berhanu Gobeza, Eshetie Molla Alemu, Wondimnew Desalegn Addis, Melkalem Mamuye Azanaw, Alemayehu Digssie Gebremariam, Desalegn Tesfa, Melaku Tadege Engidaw, Getaneh Atikilit and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC pediatrics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact, top 97% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 2 citations in OpenAlex.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Ermias Sisay ChanieDepartment of Paediatrics and Child Health Nursing, College of Health Sciences, Debre Tabor University, Debre Tabor, Ethiopia. ermisis1888@gmail.com.
Achenef Asmamaw MucheDepartment of Epidemiology and Biostatistics, University of Gondar, Gondar, Ethiopia.
Mengistu Berhanu GobezaDepartment of Paediatrics and Child Health Nursing, College of Medicine Health Sciences, University of Gondar, Gondar, Ethiopia.
Eshetie Molla AlemuDepartment of Public Health, College of Health Sciences, Debre Tabor University, Debre Tabor, Ethiopia.
Wondimnew Desalegn AddisDepartment of Public Health, College of Health Sciences, Debre Tabor University, Debre Tabor, Ethiopia.
Melkalem Mamuye AzanawDepartment of Public Health, College of Health Sciences, Debre Tabor University, Debre Tabor, Ethiopia.
Alemayehu Digssie GebremariamDepartment of Public Health, College of Health Sciences, Debre Tabor University, Debre Tabor, Ethiopia.
Desalegn TesfaDepartment of Public Health, College of Health Sciences, Debre Tabor University, Debre Tabor, Ethiopia.
Melaku Tadege EngidawDepartment of Public Health, College of Health Sciences, Debre Tabor University, Debre Tabor, Ethiopia.
Getaneh AtikilitDepartment of Public Health, College of Health Sciences, Debre Tabor University, Debre Tabor, Ethiopia.
Sofonyas AbebawTirunehDepartment of Public Health, College of Health Sciences, Debre Tabor University, Debre Tabor, Ethiopia.
Getachew ArageDepartment of Paediatrics and Child Health Nursing, College of Health Sciences, Debre Tabor University, Debre Tabor, Ethiopia.
Debre Tabor University · ETUniversity of Gondar · ET

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEven though treatment failure is higher among TB and HIV infected children in a resource-limited setting, there is no prior evidence in general and in the study area in particular. Hence, this study was aimed at determining the half-life time prediction of developing first-line antiretroviral treatment failure and its risk factors among TB and HIV co-infected children.

methodsA historical follow-up study was employed among 239 TB and HIV co-infected children from January 2010-December 2020. The data was entered into Epi data version 4.2.2 and exported to STATA 14.0 Software for analysis. The Kaplan-Meier plot was used to estimate the half-life time to develop treatment failure. The required assumption was fulfilled for each predictor variable. Additionally, those variables having a p-value ≤0.25 in the bivariable analysis were fitted into a multivariable Cox-proportional hazards regression model. P-value, < 0.05 was used to declare a significant association.

resultsA total of 239 TB and HIV co-infected children were involved in this study. The overall half-life time to develop first treatment failure was found to be 101 months, with a total of 1027.8 years' follow-up period. The incidence rate and proportion of developing first-line treatment failure were 5.5 per 100 PPY (Person-Year) [CI (confidence interval): 3.7, 6.9] 100 PPY and 23.8% (CI; 18.8, 29.7) respectively. Factors such as hemoglobin 10 mg/dl [AHR (Adjusted Hazard Ratio): 3.2 (95% CI: 1.30, 7.73), severe acute malnutrition [AHR: 3.8 (95% CI: 1.51, 79.65), World Health Organization stage IV [AHR: 2.4 (95% CI: 1.15, 4.93)], and cotrimoxazole prophylaxis non user [AHR: 2.3 (95% CI: 1.14, 4.47)] were found to be a risk factor to develop treatment failure.

conclusionIn this study, the half-life time to develop first-line treatment failure was found to be very low. In addition, the incidence was found to be very high. The presence of hemoglobin 10 mg/dl, severe acute malnutrition, World Health Organization stage, and non-use of cotrimoxazole prophylaxis were discovered to be risk factors for treatment failure. Further prospective cohort and qualitative studies should be conducted to improve the quality of care in paediatric ART clinics to reduce the incidence or burden of first line treatment failure among TB and HIV co-infected children.

Indexed as

CoinfectionHIV InfectionsSevere Acute MalnutritionTuberculosisAnti-Retroviral AgentsChildEthiopiaFollow-Up StudiesHalf-LifeHumansIncidenceRetrospective StudiesRisk FactorsTrimethoprim, Sulfamethoxazole Drug CombinationAnti-Retroviral AgentsTrimethoprim, Sulfamethoxazole Drug CombinationChildrenEthiopiaHalf-lifeTB and HIV co-infectedTreatment failure

Identifiers

PMID35241036
PMCPMC8892785
OpenAlexW4214879382

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.